294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125
Rachele Alzani(Nerviano Medical Sciences), C. Mercurio, Wilma Pastori(Nerviano Medical Sciences), Clara Albanese(University of L'Aquila), W. Croci, C. DePonti, Fulvia Roletto(Nerviano Medical Sciences), Giuseppe Locatelli, Francesco Fiorentini(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 1
Related Papers
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
|Molecular Cancer Therapeutics|2017|93